EMDA vs BCG for bladder cancer treatment
JS Medical will be exhibiting the EMDA® drug delivery system at BAUS Brighton.
Latest Data from Guy’s Trial Endorses EMDA
Latest data from Guy’s & St Thomas’ endorses intravesical sequential BCG/EMDA+MMC for HR-NMIBC
Trial finds RenalGuard Therapy® superior to POSEIDON method
REMEDIAL III trial results presented at TCT2019 in San Franciso by Dr Carlo Briguori.
RenalGuard Appoints JS Medical to UK & Ireland
RenalGuard Solutions has appointed JS Medical as their new UK and Ireland distributor.
Helping MedTech companies expand in Europe & MENA
Murat Celebi is meeting innovative MedTech companies at CIRSE2019 – is international expansion in your strategy?
Are you attending BAUS 2019?
We are counting down to BAUS 2019 in Glasgow next week.
RenalGuard at EuroPCR 2019
EuroPCR 2019 proved as informative as ever with Robin Luper delighted to share the benefits of the RenalGuard System™ with new contacts as well as catching up with colleagues.
Physion Appoints JS Consulting in MENA
Physion has appointed JS Consulting as their strategic advisor for the GCC & Middle East regions.
NICE Recommends Use of EMDA®
NICE has called for EMDA® to be used in research programmes as a treatment for bladder cancer.
RenalGuard On Television In Azerbaijan
With the first case of RenalGuard® treatment successfully undertaken in Baku, Robin Luper finds TV fame!
